TabsDetailsBasic DetailsDate: Thursday, January 19, 2012Type: PublicationMedical Product: oral antidiabetic medication, saxagliptinHealth Outcome(s): acute myocardial infarction (AMI)Description: This article describes a protocol for active surveillance of acute myocardial infarction (AMI) in users of a recently approved oral antidiabetic medication, saxagliptin, along with several comparators, and provides the rationale for decisions made in drafting the protocol. Read More Materials: Pharmacoepidemiology and Drug Safety, Volume 21, Issue Supplement S1, January 2012, Pages 282-290, DOI: 10.1002/pds.2337Additional InformationInformationPopulation / Cohort: diabeticsRelated Assessment(s): Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart FailureProspective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based StudyRisk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudySentinel Initiative Public Workshop - Ninth AnnualPDS Supplement: The U.S. Food and Drug Administration's Mini-Sentinel ProgramContributorsAuthor(s): Bruce Fireman MA; Sengwee Toh ScD; Melissa G. Butler PharmD, PhD, MPH; Alan S. Go MD; Hylton V. Joffe MD, MMSc; David J. Graham MD, MPH; Jennifer C. Nelson PhD; Gregory W. Daniel PhD, MPH, RPH; Joe V. Selby MD, MPHCorresponding Author: Bruce Fireman, Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA. E-mail: bruce.fireman@kp.org
